Patents by Inventor NIKOLAOS GEORGOPOULOS

NIKOLAOS GEORGOPOULOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition and apparatus for treatment of chemotherapy induced alopecia
    Patent number: 11077088
    Abstract: A composition for use in cooling therapy and treatment of chemically induced alopecia (CIA), said composition containing a reactive oxygen species (ROS) inhibitor.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: August 3, 2021
    Assignee: Paxman Coolers Ltd
    Inventors: Nikolaos Georgopoulos, Andrew Collett, Richard Paxman
  • Composition comprising a TNFR agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma
    Patent number: 10561639
    Abstract: A composition for the treatment of cancerous cells. The composition including a combination of at least one tumor necrosis factor receptor (TNFR) agonist and at least one thioredoxin inhibitor. This combinatorial approach involves direct inhibition of the thioredoxin molecule (and not the enzyme of Trx reductase).
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: February 18, 2020
    Assignee: University of Huddersfield
    Inventor: Nikolaos Georgopoulos
  • COMPOSITION AND APPARATUS FOR TREATMENT OF CHEMOTHERAPY INDUCED ALOPECIA
    Publication number: 20190240192
    Abstract: A composition for use in cooling therapy and treatment of chemically induced alopecia (CIA), said composition containing a reactive oxygen species (ROS) inhibitor.
    Type: Application
    Filed: June 20, 2017
    Publication date: August 8, 2019
    Inventors: Nikolaos Georgopoulos, Andrew Collett, Richard Paxman
  • COMPOSITION COMPRISING A TNFR AGONIST AND AT LEAST ONE THIOREDOXIN INHIBITOR FOR USE IN THE TREATMENT OF CARCINOMA
    Publication number: 20150366844
    Abstract: A composition for the treatment of cancerous cells. The composition including a combination of at least one tumor necrosis factor receptor (TNFR) agonist and at least one thioredoxin inhibitor. This combinatorial approach involves direct inhibition of the thioredoxin molecule (and not the enzyme of Trx reductase).
    Type: Application
    Filed: February 4, 2014
    Publication date: December 24, 2015
    Applicant: UNIVERSITY OF HUDDERSFIELD
    Inventor: NIKOLAOS GEORGOPOULOS